“Farber Disease Epidemiology” report has been added to DelveInsight
Overview of Farber Disease epidemiology, pathophysiology, various diagnostic approaches, and treatment algorithm, including detailed chapters for marketed products and emerging therapies
Download free sample copy here- https://www.delveinsight.com/sample-request/farbers-disease-epidemiology-insight
Farber Disease Overview
Farber’s disease is a rare inherited condition involving the breakdown and use of fats in the body. In affected individuals, lipids accumulate abnormally in cells and tissues throughout the body, particularly around the joints. The deficiency of an enzyme is called ceramidase resulting in the harmful accumulation of certain chemicals in the body, which causes damage and inflammation.
Farber Disease Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Key facts of Farber Disease epidemiology report
- Type 1 is the most common, or classical, form of this condition and is associated with the classic signs of voice, skin, and joint problems that begin a few months after birth.
- Types 2 and 3 generally have less severe signs and symptoms than the other types. Affected individuals have the three classic signs and usually do not have developmental delay. Children with these types of Farber lipogranulomatosis typically live into mid- to late childhood.
- Types 4 and 5 are associated with severe neurological problems. Type 4 usually causes life-threatening health problems beginning in infancy due to massive lipid deposits in the liver, spleen, lungs, and immune system tissues.
- Types 6 and 7 are very rare, and affected individuals have other associated disorders in addition to Farber lipogranulomatosis.
Farber Disease epidemiology Segmentation
- Total Prevalent Cases of Farber’s Disease in the 7MM [2017–2030]
- Age-specific Prevalent Cases of Farber’s Disease in the 7MM [2017–2030]
- Type-specific Prevalent Cases of Farber’s Disease in the 7MM [2017–2030]
- Diagnosed and Treatable Cases of Farber’s Disease in the 7MM [2017–2030]
Farber lipogranulomatosis is a rare disorder. About 80 cases have been reported worldwide. Most children with the classic form of Farber’s disease die by age 2, usually from lung disease.
Farber Disease Treatment
Treatment may require the coordinated efforts of a team of specialists. Pediatricians, physicians who specialize in the diagnosis and treatment of neurological disorders in children (pediatric neurologists), neurologists, physicians who specialize in the diagnosis and treatment of disorders of the bones and skeleton (orthopedists), physicians who specialize in the diagnosis and treatment of eye disorders (ophthalmologists), physicians who specialize in the diagnosis and treatment of skin disorders (dermatologists), speech pathologists, physical therapists, pain specialists, and other healthcare professionals may need to systematically and comprehensively plan treatment.
Researchers are studying enzyme replacement therapy (ERT) for lysosomal storage diseases such as ASAH1-related disorders. ERT involves replacing a missing enzyme in individuals who are deficient or lack the particular enzyme in question. Synthetic versions of missing enzymes have been developed and used to treat individuals with certain lysosomal diseases including Hurler syndrome, Fabry disease, and Gaucher disease. Clinical trials are necessary to determine whether ERT will be safe and effective for the treatment of ASAH1-related disorders.
Farber Disease Report Scope
- Farber’s disease report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns
- Farber’s disease Epidemiology Report and Model provide an overview of the risk factors and global trends of Farber’s disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Farber’s disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Farber’s disease
- The report provides the segmentation of the Farber’s disease epidemiology by Prevalent Cases of Farber’s disease in the 7MM
- The report provides the segmentation of the Farber’s disease epidemiology by Type-specific Prevalent Cases of Farber’s disease in the 7MM
Following is the TOC of Farber Disease Epidemiology Report
1. Key Insights
2. Farber Disease: Epidemiology Overview at a Glance
4. Executive Summary
5. Disease Overview: Farber Disease
6. Epidemiology and Patient Population
7. 7MM Epidemiology of Farber Disease
10. DelveInsight Capabilities
12. About DelveInsight
What are the reasons to buy this report?
- Develop business strategies by understanding the trends shaping and driving the global Farber’s disease market
- Quantify patient populations in the global Farber’s disease market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Farber’s disease therapeutics in each of the markets covered
- Understand the magnitude of Farber’s disease population by its Prevalence cases
- Understand the magnitude of Farber’s disease population by its Type-specific cases
- The Farber’s disease epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
- The Farber’s disease Epidemiology Model develop by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States